We have recently found that imatinib treatment shapes the BCR-ABL expression repertoire in patients from “high” in pre-therapeutic CD34+ CML clones to “low” during persistence [16•]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.